ScoreWhy is Shukra Pharmaceuticals Ltd ?
1
With ROE of 33.5, it has a Very Expensive valuation with a 19.3 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 114.26%, its profits have risen by 130.1% ; the PEG ratio of the company is 0.4
2
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Shukra Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Shukra Pharma.
114.26%
2.15
53.10%
Sensex
-8.4%
-0.65
12.97%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
38.32%
EBIT Growth (5y)
92.29%
EBIT to Interest (avg)
10.43
Debt to EBITDA (avg)
0.66
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.85
Tax Ratio
23.36%
Dividend Payout Ratio
4.57%
Pledged Shares
0
Institutional Holding
0.11%
ROCE (avg)
11.39%
ROE (avg)
22.38%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
48
Industry P/E
34
Price to Book Value
19.29
EV to EBIT
49.85
EV to EBITDA
43.87
EV to Capital Employed
22.41
EV to Sales
22.22
PEG Ratio
0.44
Dividend Yield
0.03%
ROCE (Latest)
44.96%
ROE (Latest)
33.49%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
PAT(9M)
At Rs 21.01 cr has Grown at 131.13%
NET SALES(9M)
At Rs 51.31 cr has Grown at 74.46%
-10What is not working for the Company
NET SALES(Q)
At Rs 6.30 cr has Fallen at -60.4% (vs previous 4Q average
PBT LESS OI(Q)
At Rs -0.58 cr has Fallen at -107.5% (vs previous 4Q average
PAT(Q)
At Rs -1.73 cr has Fallen at -123.7% (vs previous 4Q average
EPS(Q)
Lowest at Rs -0.04
Loading Valuation Snapshot...
Here's what is not working for Shukra Pharma.
Net Sales - Quarterly
At Rs 6.30 cr has Fallen at -60.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 15.92 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -0.58 cr has Fallen at -107.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 7.72 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs -1.73 cr has Fallen at -123.7% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 7.29 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Lowest at Rs -0.04
in the last five quartersMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
